

January 20, 2017

**Patient Information****Important information for patients using Emerade solution for injection in pre-filled pen notification**

Bausch + Lomb continue to research and improve the use of our products. Emerade solution for injection in pre-filled pen; 150, 300 & 500 mcg shelf-life has been amended from 30 months to 18 months. There are no other changes for this product and you may continue to use your pen as instructed. The shelf-life change will be implemented for any **future** Emerade 150, 300 & 500 mcg batches manufactured and released in UK. Kindly note that this change will be effective from February 2017. If you have been prescribed any batch with 30 months shelf-life as listed in Table 1, you can still continue to carry or use your pen if required and do not need to take any further action. The shelf-life can be found on the product label (refer to EXP date).

Bausch + Lomb are committed to delivering high quality products and offering clinical value to the NHS and patients. The Marketing Authorisation Holder has taken the decision to amend the Emerade finished product shelf-life as long-term testing shows that discoloration of solution and slight precipitation may occur. This is a known characteristic of adrenaline. The safety and efficacy profile of Emerade remains the same.

As with all Adrenaline Auto-injectors, patients are advised to check their Emerade pens periodically through the inspection window to make sure the solution is clear and colourless. Patients are advised to discard and replace Emerade if the solution is discoloured or contains precipitate. Please refer to your patient information leaflet, summary of product characteristics or [www.emerade-bausch.co.uk](http://www.emerade-bausch.co.uk) for full product information and training material.

**If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).**

**By reporting side affects you can help provide more information on the safety of this medicine.**

Adverse events can also be reported to Bausch + Lomb directly on 01748 828864 or e-mail [Pharmacovigilance.UK@bausch.com](mailto:Pharmacovigilance.UK@bausch.com)

Full product information can be found at: [www.medicines.org.uk/emc/search](http://www.medicines.org.uk/emc/search)

For further information please visit [www.emerade-bausch.co.uk](http://www.emerade-bausch.co.uk) or contact Bausch + Lomb on 01748 828864; e-mail: [Pharmacovigilance.UK@bausch.com](mailto:Pharmacovigilance.UK@bausch.com)

## Customer Services and Orders:

Visioncare  
T 0845 602 2350  
F 0845 602 2351Surgical  
T 020 8781 0000  
F 020 8781 0001Pharmaceutical  
T 020 8781 2991  
F 020 8781 0001Aesthetics  
T 0845 600 5212  
F 0845 600 5215


Registered Office: Bausch + Lomb House, 106 London Road, Kingston-upon-Thames, Surrey KT2 6TN Registered in London Number 143720

INVESTOR IN PEOPLE

**Table 1 Existing Emerade stocks with 30month shelf-life**

Description	Batch	Expiry date
EMERADE 150	RB0013A5A	01/04/2017
EMERADE 150	RB0013A6A	01/08/2017
EMERADE 150	RC0020A3A	01/09/2017
EMERADE 150	RD0033A6A	01/10/2017
EMERADE 150	RF0058A4F	01/11/2017
EMERADE 150	SB0015A1D	01/07/2018
EMERADE 150	SD0020A2A	01/09/2018
EMERADE 150	SH0042A1A	01/01/2019
EMERADE 300	QL0118B9B	05/01/1900
EMERADE 300	RA0009B2A	01/07/2017
EMERADE 300	RB0013B8A	01/08/2017
EMERADE 300	RC0020B1A	01/09/2017
EMERADE 300	RC0020B1C	01/09/2017
EMERADE 300	RC0020B4A	01/09/2017
EMERADE 300	RD0033B5B	01/10/2017
EMERADE 300	RA0009B2A	01/07/2017
EMERADE 300	RF0058B3F	01/11/2017
EMERADE 300	SB0015B4D	01/07/2018
EMERADE 300	SB0015B4F	01/07/2018
EMERADE 300	SB0015B5F	01/07/2018
EMERADE 300	SB0015B5C	01/07/2018
EMERADE 500	RA0009C1A	01/07/2017
EMERADE 500	RA0009C1B	01/07/2017
EMERADE 500	RA0009C3A	01/07/2017
EMERADE 500	RB0013C2A	01/08/2017
EMERADE 500	RB0013C7B	01/08/2017
EMERADE 500	RC0020C2A	01/09/2017
EMERADE 500	RD0033C4A	01/10/2017
EMERADE 500	RE0034C2A	01/11/2017
EMERADE 500	RF0058C5C	01/11/2017
EMERADE 500	SB0015C2E	01/07/2018
EMERADE 500	SD0020C3A	01/09/2018
EMERADE 500	SD0020C4A	01/09/2018
EMERADE 500	RF0058C5C	01/11/2017

Yours sincerely



Jenni White  
Business Unit Head Pharmaceuticals